Expert consensus on genetic testing in Chinese prostate cancer patients (2018 edition)

中国抗癌协会泌尿男生殖系肿瘤专业委员会前列腺癌学组

doi:10.19401/j.cnki.1007-3639.2018.08.011

您当前的位置：

首页 >

文章列表页 >

Expert consensus on genetic testing in Chinese prostate cancer patients (2018 edition)

更新时间：2026-01-27

- Expert consensus on genetic testing in Chinese prostate cancer patients (2018 edition)
- China Oncology Vol. 28, Issue 8, Pages: 627-633(2018)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2018.08.011
  CLC： R737.25
- Published Online：14 September 2018，
  
  Published：14 September 2018
- 稿件说明：
移动端阅览
中国抗癌协会泌尿男生殖系肿瘤专业委员会前列腺癌学组. 中国前列腺癌患者基因检测专家共识（2018年版）[J]. 中国癌症杂志, 2018, 28(8): 627-633.

中国抗癌协会泌尿男生殖系肿瘤专业委员会前列腺癌学组. Expert consensus on genetic testing in Chinese prostate cancer patients (2018 edition)[J]. China Oncology, 2018, 28(8): 627-633.
中国抗癌协会泌尿男生殖系肿瘤专业委员会前列腺癌学组. 中国前列腺癌患者基因检测专家共识（2018年版）[J]. 中国癌症杂志, 2018, 28(8): 627-633. DOI： 10.19401/j.cnki.1007-3639.2018.08.011.

中国抗癌协会泌尿男生殖系肿瘤专业委员会前列腺癌学组. Expert consensus on genetic testing in Chinese prostate cancer patients (2018 edition)[J]. China Oncology, 2018, 28(8): 627-633. DOI： 10.19401/j.cnki.1007-3639.2018.08.011.

摘要

随着第二代测序技术（next generation sequencing，NGS）在前列腺癌诊疗中愈加广泛地应用，前列腺癌精准诊治策略已使越来越多的患者受益。目前的研究已表明，对于同源重组修复缺陷的转移性去势抵抗性前列腺癌（metastatic castration-resistant prostate cancer，mCRPC）患者，可从奥拉帕利和铂类化疗药物中获益；针对免疫检查点抑制剂PD-1/PD-L1抗体，未经筛选的前列腺癌患者受益有限，然而错配修复缺陷及高度微卫星不稳定型前列腺癌患者则可接受PD-1抑制剂帕博利珠单抗（pembrolizumab）治疗。除提示药物敏感性外，NGS基因检测对于驱动基因突变患者发病风险的预估也起着重要作用。如何利用NGS精准定位可使前列腺癌患者获益的同时避免过度检测，以及针对突变基因进行解读提供后续诊疗建议，从而为中国前列腺癌患者制定个体化的治疗方案是我们每位临床医师面临的重要问题。为此，中国抗癌协会泌尿男生殖系肿瘤专业委员会前列腺癌学组组织专家撰写了本共识，以规范并促进NGS基因检测在前列腺癌诊疗中的应用。

Abstract

With the application of next generation sequencing (NGS) in prostate cancer more widely

more and more patients with prostate cancer have benefited from the precision treatment. Previous studies have revealed that metastatic castration-resistant prostate cancer (mCRPC) patients with homologous recombination repair defects can benefit from PARP inhibitor olaparib and platinum-based chemotherapy. As for PD-1/PD-L1

the outcome of unselected cases is limited whereas patients with mismatch repair defects have a positive reponse to pembrolizumab. In addition

the application of NGS plays an important role in predicting the cancer risk in people with gene mutations. And it is important for every clinician to consider how to precisely locate the patients likely benefitting from NGS

avoiding overdetection and provide advices based on gene mutations. In order to regulate and promote the application of NGS in prostate cancer

China Anti-Cancer Association Genitourinary Cancer Committee composed this expert consensus.

关键词

Keywords

references

Views

3316

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Chinese expert consensus on genomic testing of prostate cancer patients (the 2020 edition)

Mechanism study of MYC promoting proliferation and metastasis in prostate cancer by targeting CD47

The research on construction of the spontaneous prostate tumor and breast cancer model of Pten^fl/fl;Trp53^fl/fl;Pbsn-iCre⁺ transgenic mouse

Chinese expert consensus on perioperative integrated rehabilitation for radical prostatectomy (2024 edition)

Expert consensus of ¹⁷⁷Lu-labeled PSMA radioligand therapy for clinical practice of prostate cancer (2024 edition)

Related Author

中国抗癌协会泌尿男生殖系肿瘤专业委员会

中国临床肿瘤学会前列腺癌专家委员会

Hao LIU

Junjie SU

Shiyong XIN

Jiachen WU

Lina HE

Xinru TANG

Related Institution

Department of Urology, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology

College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology

Cancer Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

College of Life Sciences, Inner Mongolia University, Hohhot 010000, Inner Mongolia Autonomous Region

Department of General Practice, The First Affiliated Hospital of Xi'an Medical University

AI问答

⁰